Isolation of dendritic cells from umbilical cord blood using magnetic activated cell sorting or adherence

Bie,Yachun; Xu,Qiuxiang; Zhang,Zhenyu

doi:10.3892/ol.2015.3198

Isolation of dendritic cells from umbilical cord blood using magnetic activated cell sorting or adherence

Authors:
- Yachun Bie
- Qiuxiang Xu
- Zhenyu Zhang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Beijng Chao‑Yang Hospital, Capital Medical University, Beijing 100020, P.R. China
Published online on: May 11, 2015 https://doi.org/10.3892/ol.2015.3198
Pages: 67-70
Copyright: © Bie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dendritic cells (DCs) are a highly specialized type of antigen-presenting cell. The present study describes and compares two methods for preparing DCs from umbilical cord blood. The first method involves the isolation of DCs by magnetic activated cell sorting (MACS). This technique isolates CD34+ cells from cord blood and induces the formation of DCs by the addition of cytokines, granulocyte macrophage colony‑stimulating factor and interleukin‑4. The second method involves the generation of large numbers of DCs from cord blood using an adherent method, which isolates umbilical cord blood mononuclear cells and induces DCs in the same conditions as those used in MACS. The DCs were harvested following 7 days of incubation and observed with an inverted microscope. The phenotype of the cells was then analyzed by flow cytometry. The results revealed that, subsequent to 7 days of incubation, the differentiated DCs obtained using the adherent method were more mature than those isolated using MACS. However, these cells were unable to be maintained in culture for more than 9‑10 days. By contrast, the DCs derived from CD34+ cells by MACS were phenotypically stable and could be maintained for up to 3 weeks in culture. Either method produced DCs from cord blood. However, the DCs isolated using the MACS method demonstrated higher homogeneity, yield and viability than those obtained using the adherent method. Due to the various compositions of the monocyte subsets isolated, isolation methods affect the phenotypes and functions of the resultant DCs.

View Figures

View References

1	Steinman RM and Cohn ZA: Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med. 137:1142–1162. 1973. View Article : Google Scholar : PubMed/NCBI
2	Banchereau J, Briere F, Caux C, et al: Immunobiology of dendritic cells. Annu Rev Immunol. 18:767–811. 2000. View Article : Google Scholar : PubMed/NCBI
3	Schuler G, Schuler-Thurner B and Steinman RM: The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol. 15:138–147. 2003. View Article : Google Scholar : PubMed/NCBI
4	Chu CS, Boyer J, Schullery DS, et al: Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol Immunother. 61:629–641. 2012. View Article : Google Scholar : PubMed/NCBI
5	Coosemans A, Vanderstraeten A, Tuyaerts S, et al: Wilms' Tumor Gene 1 (WT1) - loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial. Anticancer Res. 33:5495–5500. 2013.PubMed/NCBI
6	Mody N, Dubey S, Sharma R, Agrawal U and Vyas SP: Dendritic cell-based vaccine research against cancer. Expert Rev Clin Immunol. 11:213–232. 2015. View Article : Google Scholar : PubMed/NCBI
7	GanjiBakhsh M, Nejati V, Delirezh N, Asadi M and Gholami K: Mixture of fibroblast, epithelial and endothelial cells conditioned media induce monocyte-derived dendritic cell maturation. Cell Immunol. 272:18–24. 2011. View Article : Google Scholar : PubMed/NCBI
8	Delirezh N, Majedi L, Asri Rezaei S and Ranjkeshzadeh H: Generation of mature monocyte-derived dendritic cells in the presence of heparin and monocyte conditioned medium: phenotypic and functional comparison. Iran Biomed J. 15:79–84. 2011.PubMed/NCBI
9	Takamizawa M, Rivas A, Fagnoni F, et al: Dendritic cells that process and present nominal antigens to naive T lymphocytes are derived from CD2⁺ precursors. J Immunol. 158:2134–2142. 1997.PubMed/NCBI
10	Ito T, Inaba M, Inaba K, et al: A CD1a+/CD11c+ subset of human blood dendritic cells is a direct precursor of Langerhans cells. J Immunol. 163:1409–1419. 1999.PubMed/NCBI
11	Cella M, Jarrossay D, Facchetti F, et al: Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med. 5:919–923. 1999. View Article : Google Scholar : PubMed/NCBI
12	Oehler L, Berer A, Keil F, et al: Generation of dendritic cells from human chronic myelomonocytic leukemia cells in fetal calf serum-free medium. Leuk Lymphoma. 38:577–586. 2000. View Article : Google Scholar : PubMed/NCBI
13	Ferlazzo G, Wesa A, Wei WZ and Galy A: Dendritic cells generated either from CD34⁺ progenitor cells or from monocytes differ in their ability to activate antigen-specific CD8⁺ T cells. J Immunol. 163:3597–3604. 1999.PubMed/NCBI
14	Broxmeyer HE, Hangoc G, Cooper S, et al: Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc Natl Acad Sci USA. 89:4109–4113. 1992. View Article : Google Scholar : PubMed/NCBI
15	Van Brussel I, Ammi R, Rombouts M, et al: Fluorescent activated cell sorting: An effective approach to study dendritic cell subsets in human atherosclerotic plaques. J Immunol Methods. 417:76–85. 2015. View Article : Google Scholar : PubMed/NCBI
16	Caux C, Massacrier C, Vanbervliet B, et al: CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. Blood. 90:1458–1470. 1997.PubMed/NCBI
17	Canque B, Camus S, Dalloul A, et al: Characterization of dendritic cell differentiation pathways from cord blood CD34(+) CD7(+)CD45RA(+) hematopoietic progenitor cells. Blood. 96:3748–3756. 2000.PubMed/NCBI
18	Ferlazzo G, Klein J, Paliard X, Wei WZ and Galy A: Dendritic cells generated from CD34+ progenitor cells with flt3 ligand, c-kit ligand, GM-CSF, IL-4 and TNF-alpha are functional antigen-presenting cells resembling mature monocyte-derived dendritic cells. J Immunother. 23:48–58. 2000. View Article : Google Scholar : PubMed/NCBI
19	Delirezh N, Shojaeefar E, Parvin P and Asadi B: Comparison the effects of two monocyte isolation methods, plastic adherence and magnetic activated cell sorting methods, on phagocytic activity of generated dendritic cells. Cell J. 15:218–223. 2013.PubMed/NCBI
20	Delirezh N and Shojaeefar E: Phenotypic and functional comparison between flask adherent and magnetic activated cell sorted monocytes derived dendritic cells. Iran J Immunol. 9:98–108. 2012.PubMed/NCBI
21	Mucci I, Legitimo A, Compagnino M, et al: The methodological approach for the generation of human dendritic cells from monocytes affects the maturation state of the resultant dendritic cells. Biologicals. 37:288–296. 2009. View Article : Google Scholar : PubMed/NCBI
22	Ackermann B, Tröger A, Glouchkova L, Körholz D, Göbel U and Dilloo D: Characterization of CD34⁺ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis. Klin Padiatr. 216:176–182. 2004. View Article : Google Scholar : PubMed/NCBI
23	Schott M, Seissler J, Feldkamp J, von Schilling C and Scherbaum WA: Dendritic cell immunotherapy induces antitumour response in parathyroid carcinoma and neuroendocrine pancreas carcinoma. Horm Metab Res. 31:662–664. 1999. View Article : Google Scholar : PubMed/NCBI
24	DeMatos P, Abdel-Wahab Z, Vervaert C, Hester D and Seigler H: Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. J Surg Oncol. 68:79–91. 1998. View Article : Google Scholar : PubMed/NCBI